by Jakub Jarolím, Business Intelligence Department
Vážený uživateli, je nám líto, ale Váš prohlížeč nepodporuje plné zobrazení webu. Doporučujeme Vám přejít na jeho aktuálnější verzi (MS Edge) nebo na některý z nejčastějších prohlížečů (Chrome, Firefox, Safari).
SOTIO Biotech
11/4/2022
March 2022 Biotechnology: Review of news from the most innovative therapeutic areas and the business development transactions
Market
NBI is down 25 % since September, number of IPOs are down to a trickle
The NBI added 5 % during March, however it is still down 25 % since September. Most of 2021’s biotech IPO class is trading below listing price; some biotechs are now worth no more than their cash. So far this year, IPOs are down to a trickle or being pulled, investors are cautious.
Antibody-Drug Conjugates
Mirvetuximab showed PFS of 10.6 months in high expression FRα recurrent ovarian cancer
Detail článkuInterleukin-15 and Interleukin-2
Nektar announced that IL-2 cytokine Bempeg with Opdivo failed in Phase 3 melanoma trial
BMS and Nektar Therapeutics announced an update following the first analysis of the Phase 3 PIVOT IO-001 study evaluating the doublet therapy of bempegaldesleukin in combination with Opdivo nivolumab compared to Opdivo monotherapy as a first-line treatment for previously untreated unresectable or metastatic melanoma.
Cell Therapies
EMA’s CHMP recommended marketing authorization for CAR-T Carvykti cilta-cel
Legend Biotech announced that the CHMP of the EMA recommended Janssen’s marketing authorization of Carvykti (cilta-cel) for the treatment of adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
Other Innovative Treatment Areas
BeiGene’s PD-1 inhibitor now approved for seven indications in China
China’s NMPA granted conditional approval to tislelizumab from BeiGene to treat adult patients with advanced unresectable or metastatic microsatellite instability-high or mismatch repair deficient solid tumors.
Sdílet na sociálních sítích